Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma (NCT03618550)

🧪 Interventions in This Study

• pembrolizumab (DRUG)
• gemcitabine (DRUG)
• vinorelbine (DRUG)
• liposomal doxorubicin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (10 Sites)

• City of Hope Cancer Center (Data Collection Only) — Duarte, California
• Stanford University Medical Center — Stanford, California
• University of Miami — Miami, Florida
• Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
• Memorial Sloan Kettering Monmouth — Middletown, New Jersey
• Memorial Sloan Kettering Bergen — Montvale, New Jersey
• Memorial Sloan Kettering Cancer Center @ Commack — Commack, New York
• Memorial Sloan Kettering Westchester — Harrison, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Memorial Sloan Kettering Nassau — Uniondale, New York

📞 Contact the Study Coordinator

Phone: (212) 639-4839

Email: moskowia@mskcc.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hodgkin Lymphoma

• Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma — Detroit, Michigan
• Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) — Birmingham, Alabama
• PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma — Houston, Texas
• Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma — Salt Lake City, Utah
• A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) — Detroit, Michigan
• Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL — Chicago, Illinois

Explore by condition: All Hodgkin Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.